Printer Friendly

THE IMMUNE RESPONSE CORPORATION'S WHOLLY OWNED SUBSIDIARY, TARGETECH INC., RECEIVES U.S. PATENT ON GENE THERAPY TECHNOLOGY

 SAN DIEGO, Dec. 2 ~PRNewswire~ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) announced today that the U.S. Patent and Trademark Office issued patent number 5,166,320 to its wholly owned subsidiary, TargeTech Inc. This patent covers methods and compositions for delivering DNA to the liver via receptors on the surface of liver cells. The inventors are Drs. George and Catherine Wu of the University of Connecticut. TargeTech has an exclusive license to the patent from the university.
 Dr. Dennis Carlo, chief scientific officer of Immune Response, commented that, "This patented technology may help gene therapy evolve from an in vitro procedure performed in a laboratory to a traditional injectable drug administered in a hospital setting."
 The Immune Response Corporation, through its wholly owned subsidiary TargeTech, is developing this core technology to treat human diseases through gene therapy. The technology is designed to enable direct intravenous injection of "gene drugs" targeted specifically to the asialoglycoprotein receptor on liver cells. This in vivo approach is intended to introduce a therapeutic gene into liver cells, where the gene is expressed and produces a protein without the use of retroviral vectors. This technology has demonstrated success in certain preclinical models of disease and may be effective in the treatment of human disease.
 TargeTech Inc. was acquired in November by The Immune Response Corporation, a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS, and for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin- dependent diabetes.
 -0- 12~2~92
 ~CONTACT: Bronwyn LeMelle of The Immune Response Corporation, 619-431-7080~
 (IMNR)


CO: The Immune Response Corporation; TargeTech Inc. ST: California IN: MTC SU:

JL-KJ -- SD002 -- 2732 12~02~92 08:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 30, 1992
Words:292
Previous Article:THREE PRESIDENTIAL CANDIDATES ELECTED FOR MAALOX MOMENT(TM) AWARDS
Next Article:SOFTWARE TOOLWORKS TO INTRODUCE GROUNDBREAKING MULTIMEDIA CD-ROMs, VIDEO FROM THE ENTIRE 20TH CENTURY; STRATEGIC ALLIANCE WITH CEL COMMUNICATIONS
Topics:


Related Articles
TARGETECH APPOINTS NORDOFF CHIEF EXECUTIVE OFFICER
PHILIP J. WHITCOME, PH.D., NAMED TO TARGETECH'S BOARD OF DIRECTORS
THE IMMUNE RESPONSE CORPORATION FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR SECOND RHEUMATOID ARTHRITIS TREATMENT
THE IMMUNE RESPONSE CORPORATION REPORTS FIRST QUARTER 1993 FINANCIAL RESULTS
RESULTS OF HIV IMMUNOTHERAPEUTIC PHASE II/III CLINICAL TRIAL DEMONSTRATE EFFECT ON VIRAL BURDEN IN HIV-INFECTED INDIVIDUALS
THE IMMUNE RESPONSE CORPORATION ANNOUNCES SECOND QUARTER 1993 FINANCIAL RESULTS
THE IMMUNE RESPONSE CORPORATION FILES TWO INVESTIGATIONAL NEW DRUG APPLICATIONS FOR AUTOIMMUNE DISEASE TREATMENTS
THE IMMUNE RESPONSE CORP. BEGINS THIRD CLINICAL TRIAL OF RHEUMATOID ARTHRITIS TREATMENT
THE IMMUNE RESPONSE CORPORATION BEGINS CLINICAL TRIAL OF MULTIPLE SCLEROSIS TREATMENT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters